Response to Share Price Movement
5 April 2024
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Response to Share Price Movement
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, notes recent bulletin board speculation about a placing that the Company may be undertaking.
The Company recently engaged its advisers to commence a process of market soundings in relation to a potential fundraise. However, in response to incorrect bulletin board comments regarding a speculative placing price and resulting unusual share price movements, the Board has decided to not proceed with any potential placing at this time.
As previously announced, Roquefort Therapeutics remains focused on completing an out-licensing agreement during the course of 2024 with potential Big Pharma partners and will update the market when a binding agreement is entered into.
ENDS
Enquiries:
|
Roquefort Therapeutics plc |
|
|
Stephen West (Chairman) / Ajan Reginald (CEO) |
+44 (0)20 3918 8633
|
|
Hybridan LLP (Joint Broker) Claire Louise Noyce
Optiva Securities Limited (Joint Broker) |
+44 (0)203 764 2341 |
|
Christian Dennis
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
|
+44 (0)20 3411 1881
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK cell-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 8 hours ago SSP Group
- 10 hours ago Card Factory
- 10 hours ago HSBC Holdings
- 10 hours ago Direct Line Insurance Group
- 11 hours ago CRH (CDI)